For up to eight months, Regeneron’s antibody medication protects against Covid
Clinical trials have found that just one dose of the treatment significantly reduced infection risk from Covid by 81.6%. Immunocompromised patients may benefit from this medication.
Covid-19 risk was lowered by 81.6 percent in a late-stage experiment after a single dose of Regeneron Pharmaceuticals’ antibody cocktail was administered for two to eight months.
Immunoglobulin therapy may be used to prevent Covid in patients who have not been exposed to the virus, if the results of this study support the ongoing regulatory review.
To treat persons with mild to moderate Covid and prevent infection in those who have been exposed to infected individuals, the antibody therapy REGEN-COV has been approved by the United States Food and Drug Administration.
Regeneron’s antibody cocktail may see an increase in sales when oral Covid-19 pills created by Pfizer and Merck compete with Regeneron’s antibody cocktail.
To help those with compromised immune systems and those who are unable to receive vaccines, Myron Cohen, who heads the National Institutes of Health-sponsored COVID-19 Prevention Network, said that data showed that Regeneron’s drug has the potential to provide long-lasting immunity from Covid infection.